The US FDA on February 15, 2022 has scheduled a Vaccines and Related Biological Products Advisory Committee (VRBPAC) to discuss a request to amend the Emergency Use Authorization (EUA) of the Pfizer-BioNTech’s COVID-19 mRNA vaccine for administration to children 6 months through 4 years of age.
Back to All Events
Earlier Event: February 10
Oncologic Drugs Advisory Committee
Later Event: February 15
Joint Meeting of the Committee and the Drug Safety and Risk Management Advisory Committee